Conflicts of interest have kept Lars Rebien Sørensen away from pharmaceutical boards – until now

Up until now, Lars Rebien Sørensen has refrained from taking on board roles at pharmaceutical companies due to the risk of conflicts of interest. Now, the chairman of the Novo Nordisk Foundation will be taking on the role of chairman of the board at Ferring, although he highlights one possible conflict of interest with Denmark's largest pharmaceutical giant.

Lars Rebien Sørensen, chairman of the board of directors at Novo Nordisk Fonden and Ferring Pharmaceuticals

As the future chairman of Ferring Pharmaceuticals, Lars Rebien Sørensen will soon be taking on his first board role within the pharmaceutical industry.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs